We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Binding thermodynamics of substituted diaminopyrimidine renin inhibitors

Analysis of data from the 1999-2002 National Health and Nutrition Examination Survey (NHANES)* indicated that an estimated 65 million individuals in the United States have hypertension. This analysis also determined that only 63.4% of the individuals sampled knew they were hypertensive, 45.3% were being treated, 29.3% had their blood pressure under control, but 70.7% of the total hypertensive population (~46 million people) did not1. Comparison of this data to earlier data indicated that since 1960 there have been improvements in awareness, treatment, and control of hypertension, but there is substantial room to improve both the identification of individuals at risk for hypertension and the treatment options. Current treatment options for hypertension range from lifestyle modifications, including lowering salt intake and reducing weight, to pharmaceutical intervention. Pharmaceutical therapies currently available include diuretics, alpha-blockers, alpha-beta-blockers, beta-blockers, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin II receptor blockers (ARB).